Jeff Yass’s IO Biotech IOBT Stock Holding History

Jeff Yass’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-26,676	Closed	-$141K	–	13389
2022 Q1	$141K	Buy	+26,676	New	+$176K	﹤0.01%	11613

Other funds holding IOBT

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Capital World Investors

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Millennium Management

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's IOBT Position: Q2 2022 in Review

Jeff Yass sold out of IO Biotech (IOBT) in Q2 2022, closing a stake of 26,676 shares — an estimated $141K sold.

Jeff Yass first reported a position in IOBT in Q1 2022 and held it in 1 quarter. The position peaked at $141K in Q1 2022. 18 funds tracked by Wall St. Rank hold IOBT as of Q2 2022.

Jeff Yass reported no remaining IO Biotech position as of Q2 2022 after selling out during the quarter.
Jeff Yass sold 26,676 IO Biotech shares in Q2 2022, an estimated $141K.
Jeff Yass first reported a position in IO Biotech in Q1 2022 and held it in 1 quarter.
Jeff Yass's IO Biotech position peaked at $141K in Q1 2022.
18 funds tracked by Wall St. Rank held IO Biotech as of Q2 2022.

Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.